lerodalcibep

AssetAlso called HST101, LIB003, Lyrokaul

Inhibits PCSK9, preserving LDL receptors and increasing clearance of LDL cholesterol from blood.

Stage
Approved
Modality
Protein or enzyme
Target
PCSK9
17
Indications
12
Trials
2
Developers

Approved by the FDA on Dec 12, 2025 (BLA761427). FDA

Indications

17
  • Hypercholesterolemia

    Approved, FDA

  • Heterozygous familial hypercholesterolemia

    Approved, FDA

  • Familial hypercholesterolemia

    Approved, libtherapeutics.com

14 more

In the full profile

  • Target and mechanism1
  • Owner and partners2
  • Trials12
  • Evidence for its targets2
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets